RLMDRelmada Therapeutics, Inc.
What is the market doing?
The market is leaning against it: in a downtrend (−39% vs 200-day) and heavily shorted (+13% of shares).
In a downtrend, below its 50- and 200-day averages. Price is −39% vs its 200-day average.
Heavily shorted, settled Sep 30, 2026, more than a week of normal trading to cover, a crowded exit.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How RLMD is trading
Relmada Therapeutics, Inc. is +53% over the past year while the S&P 500 is +16%: 37 points ahead of the market.
1-year return · S&P 500 +16%
- vs 200-day average
- −39%
vs 200-day average · a clear downtrend
- RSI (14)
- 43
RSI (14) · neutral
- Below its 52-week high
- 58%
Below its 52-week high
Details›
- Last close2026-10-23
- $3.27
- 1 monthS&P 500 −0.94%
- −14%
- 1 yearS&P 500 +16%
- +53%
- 5 yearsS&P 500 +86%
- −86%
- vs 50-day average$3.99
- −18%
- 52-week high
- $7.86
- 52-week low
- $2.10
- Annualised volatility
- 139%
| Year | Return |
|---|---|
| 2026 (year to date) | −32% |
| 2025 | +829% |
| 2024 | −87% |
| 2023 | +19% |
| 2022 | −85% |
| 2021 | −30% |
| 2020 | −18% |
| 2019 | +748% |
| 2018 | +53% |
| 2017 | −31% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 5 of 10 | −2.1% |
| Feb | 10 | 5 of 10 | +2.8% |
| Mar | 10 | 7 of 10 | +7.4% |
| Apr | 10 | 8 of 10 | +12% |
| May | 10 | 4 of 10 | +13% |
| Jun | 10 | 1 of 10 | −12% |
| Jul | 11 | 6 of 11 | +2.5% |
| Aug | 11 | 4 of 11 | +2.2% |
| Sep | 11 | 9 of 11 | +16% |
| Oct | 11 | 4 of 11 | +3.5% |
| Nov | 10 | 3 of 10 | +2.4% |
| Dec | 10 | 5 of 10 | +1.4% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.